6-Month Open-Label Safety Study Of PD 0332334 In Elderly Patients With Generalized Anxiety Disorder (GAD)

Last updated: November 30, 2012
Sponsor: Pfizer
Overall Status: Trial Not Available

Phase

3

Condition

Panic Disorders

Anxiety Disorders

Mood Disorders

Treatment

N/A

Clinical Study ID

NCT00738738
A5361036
  • Ages > 65
  • All Genders

Study Summary

This is an open-label, multi-site, 6-month study of an investigational compound in elderly outpatients, age 65 years old or above, to assess the long-term safety and tolerability of the compound in the treatment of elderly subjects with Generalized Anxiety Disorder (GAD).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Men or women age > 65 years.

  • A primary diagnosis of Generalized Anxiety Disorder according to the Diagnostic andStatistical Manual-IV (DSM-IV).

  • Subjects must have a HAM-A score of 16 or higher at both screening and baselinevisits.

Exclusion

Exclusion Criteria:

  • Women who are pregnant or contemplating pregnancy (eg, via in vitro fertilization)during the study through 30 days after the last dose of study medication.

  • Subjects with evidence of a current (within the past 6 months) clinically significantor unstable hematological, autoimmune, renal, endocrine, pulmonary, gastrointestinal,cardiovascular, hepatic, pancreatic, psychiatric, neurologic, immunological or retinaldisorder; subjects with an active infection within the past 2 months.

  • Subjects who have an ongoing, unresolved, clinically significant cardiovascular orcerebrovascular medical problem.

  • Mini Mental Status Exam (MMSE) score <24 or possibility of undiagnosed dementia,cognitive or amnestic disorder, including, but not limited to mild cognitiveimpairment.

Study Design

Study Start date:
January 01, 2009
Estimated Completion Date:
February 28, 2009

Study Description

Termination reason: On February 23rd 2009, a decision to terminate further development for PD 0332334 was communicated to investigators in this study. The decision to terminate this study was not based on any safety concerns.

Connect with a study center

  • Pfizer Investigational Site

    Orlando, Florida 32806
    United States

    Site Not Available

  • Pfizer Investigational Site

    Prairie Village, Kansas 66206
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.